VBI Vaccines Expands Proprietary Technology Platforms With Development Of A Novel mRNA-Launched eVLP Vaccine Program
Portfolio Pulse from Benzinga Newsdesk
VBI Vaccines Inc. (NASDAQ:VBIV) has announced the development of its next-generation mRNA-launched enveloped virus-like particle (eVLP) technology. The new technology has shown in preclinical studies to generate stronger B- and T-cell signals than other mRNA vaccines tested. It also offers streamlined and accelerated manufacturing processes. The technology is currently under evaluation by multiple potential partners, including pharmaceutical and biotechnology companies.
October 26, 2023 | 12:20 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
VBI Vaccines' new mRNA-launched eVLP technology could potentially enhance the company's product portfolio and attract partnerships. The technology's ability to generate stronger immune responses and accelerate manufacturing processes could be beneficial for the company.
The development of the new mRNA-launched eVLP technology could potentially enhance VBI Vaccines' product portfolio and make it more attractive to potential partners. The technology's ability to generate stronger immune responses and accelerate manufacturing processes could be beneficial for the company in terms of product development and production efficiency. This could potentially lead to increased revenues and profitability in the future.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 100